Trial Profile

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Venetoclax (Primary) ; Bendamustine
Indications Mantle-cell lymphoma
Focus Therapeutic Use

Most Recent Events

13 Jun 2025 Status changed from recruiting to discontinued because the sponsor withdrew funding early, forcing this study to stop all activity and close pre-maturely.
20 Apr 2022 Planned initiation date changed from 15 Mar 2022 to 15 Jun 2022.
10 Feb 2022 Planned initiation date changed from 15 Dec 2021 to 15 Mar 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com